chemieunternehmen.com

Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/medicinal-chemistry-collaboration-with-active-biotech-5006

Evotec AG and Galapagos NV today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/compound-management-business-from-galapagos-acquired-5004

Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-received-as-boehringer-ingelheim-starts-phase-i-clinical-trial-in-pain-5002

Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/strategic-alliance-with-psychogenics-entered-to-provide-integrated-cns-drug-discovery-solutions-5000

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-4998

Evotec AG today reported financial results and corporate updates for the first quarter of 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-54-q1-revenue-growth-and-significant-expansion-of-drug-discovery-alliance-business-4996

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/twelfth–milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-4994

Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/acquisition-of-kinaxo-biotechnologies-gmbh-completed-4990

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2010. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/full-year-2010-results-a-good-year-with-a-strong-start-into-2011-4988